Study details
Enrolling now
A Study of NT-175 in Adults With Advanced Solid Tumors
AstraZeneca
NCT IDNCT05877599ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
162
Study length
about 16 years
Ages
18+
Locations
18 sites in AZ, CA, FL +9
What this study is about
This trial is testing a new treatment called NT-175, which are engineered T cells. The goal is to see if this treatment can help people with advanced solid tumors that have specific genetic changes.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Autologous, engineered T Cells targeting TP53 R175H
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Oncology